September 13, 2021

ESMO 2021 Clinical Panel: Melanoma

September 21, 2021

ESMO 2021 Clinical Panel: Melanoma


LARVOL is pleased to present a moderated discussion with top oncologists following the ESMO Congress 2021. In the video below, Dr. Diwakar Davar, Dr. Pauline Funchain and Dr. Jennifer McQuade discuss the practice-changing impact of ESMO presentations in Melanoma.

On September 20th, 2021, LARVOL hosted an Oncology Panel to discuss the top Melanoma clinical trial abstracts presented during the ESMO Congress 2021 , held on September 16-21, 2021. Dr. Diwakar Davar from UPMC Hillman Cancer Center moderated the discussion between Melanoma experts Dr. Pauline Funchain from Taussig Cancer Institute at Cleveland Clinic and Dr. Jennifer McQuade from MD Anderson Cancer Center.

The discussion covered ESMO Melanoma Abstracts:

  • 1036O: Relatlimab (RELA) + nivolumab (NIVO) vs. NIVO in previously untreated metastatic or unresectable melanoma: Additional efficacy in RELATIVITY-04
  • LBA3_PR: Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial 
  • 1039MO: CheckMate 204: 3-year outcomes of treatment with combination nivolumab (NIVO) plus ipilimumab (IPI) for patients (pts) with active melanoma brain metastases (MBM)


Watch this video for the full discussion: 

Download attached file

Subscribe to our newsletter

Sign up for our newsletter to get the latest news, updates and high-impact data delivered directly to your inbox.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.